Introduction
Chronic kidney disease (CKD) affects a considerable proportion of the world population, especially the elderly. The World Health Organization (WHO) estimated that in 2012, more than 800,000 deaths were attributable to this entity, representing 1.5% of global mortality, 1.1% (2,968,000) of disability adjusted life years (DALYs) lost and 1.3% (2,546,700) years of potential lost life (YPLLs) worldwide [1] . CKD ranks as the 14 th cause of death globally at a rate of 12.2 deaths per 100,000 population. In Spain, the prevalence of stage 3 and 4 CKD is 6.8% in the general population, and 21.42% in people aged 65 or older, constituting a public health problem of great impact [2] .
Vitamin D, for its part, is a hormone with clearly established effects in the mineral and bone metabolism; however, recent studies are revealing novel pleiotropic effects as a result of the activation of the vitamin D receptor (VDR) in different tissues. These discoveries could lead to a revolution in the management of vitamin D in several pathologies to which it is related. In addition to its association with musculoskeletal diseases like rickets and osteomalacia, vitamin D de iciency has been linked with chronic diseases like chronic pulmonary obstructive disease (COPD) and hypertrophic cardiopathy [3] . Hypovitaminosis D is highly prevalent in patients with CKD from the earliest stages of the disease, but it also seems to be very common at subclinical levels in the general population, with an uncertain signi icance.
We undertook a literature review to assess data on cardiovascular events and the potential prognostic implications of vitamin D de iciency in patients with stage 3 and 4 CKD. stimuli that increase production of vitamin D depend on blood calcium and phosphate levels. Hypocalcemia stimulates the secretion of parathyroid hormone (PTH), which in turn prompts the production of 1-α-hydroxylase. A phosphate-poor diet also directly stimulates this enzyme. Moreover, 1-α-hydroxylase is inhibited by high levels of blood calcium and a high concentration of both calcitriol (negative feedback) and ibroblast growth factor 23 (FGF23). These factors also contribute to the inhibition of calcitriol, stimulating 24-hydroxilase, which degrades both calcitriol and calcifediol.
FGF23 has an important role in the early pathogenesis of vitamin D de iciency in CKD. This phosphaturic hormone is secreted by osteocytes and osteoblasts to maintain phosphate homeostasis, especially in an early stage of kidney disease. FGF23 is regulated by its co-receptor, Klotho protein, which increases the af inity of the FGF23 to its receptor and regulates FGF23 synthesis [4] .
Vitamin D receptor (VDR):
The hormonal 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) acts primarily through its union to the vitamin D receptor (VDR), a member of the nuclear hormone receptor family. In turn, 25(OH)D 3 is also capable of binding to the VDR and activating it. Although its af inity is 200 times less, this is compensated for by a serum concentration 500 times higher (Table 2 ) [5] .
VDR is a transcription factor, so the main action of 1,25-dihydroxyvitamin D 3 is to regulate gene expression in target tissues. Traditionally, these have been considered to be the small intestine, the bone, the kidneys, and the parathyroid glands. However, studies have also demonstrated the presence of both 1-α-hydroxylase and VDR in the cells of other tissues, for example in the brain, heart, pancreas, vascular endothelium, and prostate, among other sites (Table  3) . As a result, there is increasing knowledge on the effects derived from VDR activation [4] .
In addition to vitamin D's well-known functions in regulating blood calcium as well as bone metabolism and mineralization, recent studies [4] point to a variety of other effects it has on different tissues. The activation of extraskeletal VDR participates in the regulation of the
Material and Methods
We included original articles, reviews, clinical trials, and meta-analyses of trials with the primary objective of assessing the prognostic implications of vitamin D de iciency in adults with CKD. Primary outcomes were mortality and cardiovascular events.
Search strategy
We searched Google Scholar, MEDLINE and UpToDate for documents and clinical practice guidelines published by different societies and professional associations, both in Spain and internationally, on CKD and on vitamin D (epidemiology of hypovitaminosis and its physiological effects). Secondly, we performed a search for records relating the two entities, focusing on both the prevalence of vitamin D de iciency in these patients and the prognostic implications of vitamin D in CKD. We narratively reviewed the papers of the most importance or which presented the best evidence in relation to the primary objective of the review, as judged by the irst author. The search period was limited to the most recent 10 years, with the search beginning in October 2008. We reviewed the bibliographies of included papers to verify the basis of their conclusions, identify further related papers, and draw our own conclusions about the body of evidence. A total of 26 manuscripts were choosen. Table 1 shows the search terms used during the MEDLINE search. In Google Scholar, we ran different searches with terms like "Cardiovascular events in patients CKD 25(OH)D 3 Vitamin D," "Vitamin D mortality CKD adults," "Pleiotropic effects vitamin D VDR," and "Progression Chronic Kidney Disease Vitamin D levels". In UpToDate, the current reviews were analyzed on: "Vitamin D de iciency in adults", "Overview of chronic kidney disease-mineral and bone disorder" and "Vitamin D and extraskeletal health".
Data analysis
The results of the literature review were structured into two subsections: irst, on aspects related to the synthesis and metabolism of vitamin D, its pleiotropic effects, and the role of vitamin D de iciency in the general population; and second, the studies relating hypovitaminosis D with CKD, from its pathogenesis to the prognostic implications in this pathology. 
Results
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immune system and in lammation, the skeletal muscle, the energy metabolism, the cardiovascular system, and the modulation of cell proliferation. Some of the key functions of vitamin D, of special importance in CKD, include the reduction of in lammation and adipogenesis, maintenance of normal blood pressure, adequate insulin secretion, improvement of peripheral insulin resistance, regulation of cholesterol levels, and increase of vascular endothelial cell function.
Concept of suf iciency and prevalence of hypovitaminosis in the general population: The criteria to de ine optimal values of 25(OH)D 3 are mainly based on the levels needed to obtain the maximum suppression of the PTH, to produce enough 1,25 vitamin D to ensure intestinal absorption of calcium, and to prevent clinical events related to its de iciency (fractures) [6] . Vitamin D de iciency is de ined as levels of 25(OH)D 3 of less than 20 ng/mL (50 nmol/L), and insuf iciency as levels of 20 ng/mL to 30 ng/mL in blood [6] .
In a review 7 of the prevalence of hypovitaminosis D in the general population of the United States, inadequate levels were detected in healthy children, young adults (especially African Americans), and the elderly. The prevalence of 25(OH)D 3 levels under 20 ng/mL was approximately 36% in young adults aged 18 to 29 years, 41% in ambulatory patients aged 41 to 83 years, and up to 57% in hospitalized patients. The situation was similar in Europe, where the prevalence of de iciency was up to 30% in healthy adults and up to 70% in inpatients [8] . In patients with CKD, both insuf iciency and de iciency of vitamin D may reach a prevalence of more than 80% 9 . It is noteworthy that the European Action on Nutrition and Health-Survey (EURONUT-SENECA) showed lower levels of vitamin D in Mediterranean countries (Italy, Greece, Spain), considered sunny countries, than in others like the Netherlands or Finland.
Prognostic implications of vitamin D in CKD
In the early stages of CKD, the production of calcitriol (1,25 dihydroxyvitamin D 3 ) slows down for various reasons: i) a decrease in the glomerular iltration rate (GFR), which in turn reduces the substrate for the conversion of the 25(OH)D 3 to calcitriol; ii) a decrease in megalin expression; iii) the loss of 1-α-hydroxylase due to the structural renal commitment and the suppression of its activity, stemming from an increase in the FGF23 levels; and iv) the stimulation of the 24-hydroxylase enzyme. In more advanced stages of kidney disease, proteinuria begins to gain importance in vitamin D de iciency [10] .
The already high prevalence of vitamin D de iciency rises even more as CKD progresses. In a Spanish cohort of patients with CKD not on dialysis [11] , 51% presented levels of 25 (OH)D 3 of less than 15 ng/mL, while just 10% had levels above 30 ng/mL. Calcitriol levels generally drop when the GFR is less than 60 mL/min, although low concentrations have been observed even when GFR is less than 80 mL/min [12] . Initially, this decrease in calcitriol is probably due to the increase in FGF23; however, in advanced stages of CKD, hyperphosphatemia and the loss of renal mass are more important in reducing the synthesis of calcitriol [13] .
Phosphate retention has been considered the initial trigger of the alterations associated with CKD. The tendency to retain phosphate contributes to hyperparathyroidism secondary to CKD, in part because of the decrease in both blood calcium and calcitriol synthesis. However, levels of serum phosphate are not elevated in most patients with early stage CKD, probably because of a reduction in the tubular reabsorption of phosphate mediated by PTH and FGF23. Levels of calcitriol, FGF23, and its co-receptor Klotho suffer alterations before PTH does (Figure 1 ).
FGF23, in the presence of Klotho, diminishes the synthesis of calcitriol by suppressing the activity of 1-α-hydroxylase and stimulating the 24-hydroxilase enzyme. FGF23 levels were measured in a cohort of CKD, these levels were quite stable over time in most of the patients but in those with rising levels, where a higher risk of death was found. Moreover, higher FGF23 was independently associated with increased risk of death in multivariable-adjusted analyses of time-varying FGF23 [14] . In a 2017 cohort study of older people with CKD, Shardlow et al., analyzed elevated PTH, Vitamin D de iciency and elevated FGF23 levels as risk factors for all-cause mortality. They found vitamin D de iciency and elevated PTH were independent risk factors for all-cause mortality but elevated FGF23 was not [15] .
Klotho increases the af inity of FGF23 to its receptor and regulates its synthesis, so that low levels of Klotho increase levels of FGF23. Moreover, emerging research is showing that Klotho is involved in multiple processes related to endothelial function, renal ibrosis, and cardiomyopathies. The production of Klotho is mainly renal, and its concentration decreases early in CKD, to the point that it could be considered an important biomarker in this entity. According to the latest research, Klotho may be a sensible biomarker for early diagnosis and a reliable prognostic indicator of renal progression and the development of cardiovascular diseases in CKD. However, more research is needed to assess this question [16] . 
Cardiovascular morbimortality in patients with CKD:
The main cause of death in patients with CKD is by far cardiovascular disease [1] . It is known that CKD is a powerful predictor of adverse clinical outcomes and only a small minority of patients with CKD progress to the end stage renal disease with death prior to renal replacement therapy. Indeed, cardiovascular mortality is estimated to be up to 57% higher in patients with a GFR of less than 60 mL/min compared to patients without CKD. The risk that these patients present a non-fatal myocardial infarction increases by 33% when the GFR is less than 60 mL/min and by 48% in the presence of microalbuminuria. Moreover, for each 10 mL/ min decrease in GFR, the risk of stroke increases by 7%, or by 10% for each 25 mg/mmol increase in the albumin:creatine ratio [1, 14, 17, 18] (Table 4) . On the other hand, proteinuria is now widely accepted as an early indicator of renal injury that can be detected earlier than any tangible decline in GFR, as well as independent predictor of cardiovascular mortality and morbidity, addressing the role of proteinuria as a cardiovascular risk marker, and being evolved into a therapeutic target for cardiovascular risk reduction. An interesting review conducted by Currie and Delles [14] , demonstrated the clear association between the presence of proteinuria and cardiovascular outcomes, not only in those with CKD, but in both diabetic and hypertensive patients, letting us consider proteinuria as a surrogate marker of cardiovascular risk.
In luence of vitamin D in cardiac structure and function: Experimental data [19] suggest that vitamin D's intracellular pathways are involved in modifying cardiac structure and function. However, only limited evidence is available. In 2008, the PRIMO clinical trial assessed the effects of administering vitamin D (paricalcitol) in the mass of the left ventricle following 48 weeks of treatment in patients with CKD not on dialysis. The results were not statistically signi icant, showing no differences between the intervention and placebo groups. Later, in a post-hoc analysis, investigators observed that the vitamin D therapy reduced the levels of pro b-type natriuretic peptide as well as cardiovascular admissions (mainly due to congestive heart failure) in the group treated with paricalcitol. Based on this analysis, it seems that vitamin D has a role in cardiovascular function, although this would have to be demonstrated in future trials [19] .
Association between vitamin D and endothelial function: Calci ication and arterial rigidity are frequent indings in patients with CKD, and they in luence cardiovascular mortality. Endothelial dysfunction can also be considered a factor in cardiovascular disease, and it appears to be associated with vitamin D de iciency. A cross-sectional study in 214 patients with CKD showed an independent association between low levels of 25(OH)D 3 in blood and vascular calciication, as measured via radiodiagnosis [20] . Chitalia et al. [21] , demonstrated that patients with CKD and vitamin D levels of 37.5 nmol/L (10.82 ng/ml) or less show nearly twice the endothelial dysfunction (measured non-invasively using low-mediated dilatation of the brachial artery) than those with higher levels.
Vitamin D levels affect survival in people with CKD, regardless of cardiovascular risk
A prospective cohort study [22] followed 140 patients with CKD at any stage for almost two years, studying the relationship between levels of vitamin D (25(OH)D in blood), vascular calci ication, and mortality. Authors observed a signi icant association between low levels of serum 25(OH) D and mortality, independently of vascular calci ication. Speci ically, the study showed higher all-cause mortality rates in patients with 25(OH)D under the cutoff of 16.7 ng/mL.
Levels of vitamin D and progression of kidney disease:
Animal models [23] suggest an important potential role for vitamin D in slowing the progression of kidney disease. These effects, through which vitamin D can theoretically protect renal structure and function, mainly consist of the suppression of the renin-angiotensin-aldosterone system, plus anti-in lammatory, antioxidant, and antiproliferative effects.
However, despite the plausible mechanisms through which vitamin D can exercise a protective renal effect, studies in humans are not entirely consistent. In a 2017 review, Mehrotra [23] analyzed the relationship between vitamin D and progression of kidney disease, as well as vitamin D's role in preventing and reducing proteinuria. The review concluded that low vitamin D is an important predictor of microalbuminuria, and treatment with vitamin D analogs has an anti-proteinuric effect. However, despite the association shown between increased proteinuria and CKD progression, there is no consensus about whether all anti-proteinuric therapies can slow the progression of kidney disease. Thus, although numerous cohort studies have demonstrated that low levels of 25(OH)D 3 in blood are consistently associated with reduced GFR and faster progression to dialysis, most of the clinical trials analyzed were unable to show any bene icial effect of vitamin D supplementation for delaying the progression of kidney disease. In fact, some of these studies even signaled that treatment with analogs was related to larger decreases in the iltration. It is still unclear whether vitamin D contributes to slowing CKD or if supplementation could be renoprotective in these patients. New clinical trials would be necessary to assess this hypothesis.
Vitamin D levels and mortality in patients with CKD: Vitamin D de iciency has been associated with cardiovascular risk and premature death in patients with CKD on hemodialysis. However, this association is not wellknown in the stages prior to dialysis. One cohort study [ 24] in more than 3000 patients not under dialysis in the United States observed a relationship between hypovitaminosis D and all-cause mortality. As levels of 25(OH)D 3 decreased, the hazard ratio for all-cause death increased. Likewise, in another cohort study, Pietro Ravani et al. [25] analyzed the prognostic implication of vitamin D levels in patients with CKD not on dialysis, concluding that 25(OH)D 3 of less than 15 ng/mL is predictive of a faster progression to dialysis and death. In a meta-analysis including patients with CKD, Stefan Pilz et al. [26] , found that low levels of vitamin D were associated with higher mortality. These investigators included 10 studies involving 6800 patients, and the results showed a clear association between levels of 25(OH)D 3 and mortality in patients with CKD. Analyzing vitamin D levels categorially (< 10 ng/mL, 10 ng/mL to 20 ng/mL, 21 ng/mL to 30 ng/mL, and > 30 ng/mL), investigators found that for every 10 ng/mL increase in 25(OH)D 3 , mortality decreased by 14%. Finally, Navaneethan et al. [27] found that 25(OH) D 3 levels of less than 15 ng/mL increased the risk of all-cause mortality by as much as 33%.
Vitamin D treatment for decreasing mortality and cardiovascular risk in CKD patients: Vitamin D supplementation rates has risen signi icantly among CKD patients during the last decade, and it has been associated with greater serum 25(OH)D levels. However, the effect on mortality remains unclear [28] .
A review [29] showed that vitamin D therapies (25(OH) D 3 , calcitriol, or synthetic derivatives) decreased mortality more than placebo or no intervention in patients with CKD. A meta-analysis [30] assessed treatment with different oral vitamin D analogs for reducing mortality and cardiovascular disease in patients with CKD. The 13 included studies, involving nearly 1500 patients, did not show a signi icant effect of treatment for all-cause (RR 0.84, 95% CI 0.47 to 1.52) or cardiovascular (RR 0.79, 95% CI 0.26 to 2.28) mortality compared to the placebo group. The review authors concluded that there was insuf icient evidence to show how vitamin D supplementation affected these patients.
However, in another meta-analysis [31] , including 21 studies and 908 patients with CKD not on dialysis, paricalcitol (selective VDR activator) decreased the risk of cardiovascular events compared to the control group (RR 0.30, 95% CI 0.16 to 0.56; p< 0.001). Thus, although it seems clear that paricalcitol reduces the number of cardiovascular events in this population, more studies are needed that speci ically aim to assess vitamin D treatment for reducing all-cause and cardiovascular mortality.
Conclusion
There is a considerable prevalence of hypovitaminosis D in the general population. In people with CKD, vitamin D insuf iciency and de iciency may reach a prevalence of more than 80%. Vitamin D levels begin to fall in the early stages of CKD, even with GFRs of more than 60 mL/min. CKD and its progression are associated with cardiovascular complications and high mortality. Vitamin D has an important prognostic role in CKD. Low levels are independently associated with greater all-cause mortality and especially with greater cardiovascular risk in patients with CKD not on dialysis.
Treatment with paricalcitol seems to reduce cardiovascular mortality-the primary cause of death in CKD; however, more trials are needed with the primary objective of relating vitamin D treatment to reduced mortality and of comparing different treatment options with vitamin D analogs.
